Pharmacotherapy for benign prostatic hyperplasia -the potential for α-adrenoceptor subtype-specific blockade

British Journal of Urology

Volumn 81, Issue SUPPL. 1, 1998, Pages 34-47

  Chapple, C R ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; DOXAZOSIN; ENALAPRIL; ESTROGEN; FINASTERIDE; GONADORELIN; NIFEDIPINE; PRAZOSIN; TAMSULOSIN; TERAZOSIN;

ASTHENIA; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HEADACHE; HUMAN; MALE; MALE SEXUAL DYSFUNCTION; META ANALYSIS; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SOMNOLENCE; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; CLINICAL TRIALS; DOXAZOSIN; HORMONES; HUMANS; MALE; PATIENT SELECTION; PLANT EXTRACTS; PRAZOSIN; PROSTATIC HYPERPLASIA; QUINAZOLINES; SULFONAMIDES;

EID: 0031857722     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1998.0810s1034.x     Document Type: Article

References (110)

1. Abrams P. New words for old: lower urinary tract symptoms for 'prostatism' [editorialJ. Br Med J 1994: 308: 929-30
2. Cutinha PE, Potts KL, Rosario DJ, Hastie KJ, Moore KT, Chappie CR. A prospective audit of the use of a prostate clinic Br JUrol 1996; 78: 733-6
3. Neal DE, Ramsden PD, Sharpies L et al. Outcome of elective prostatectomy. Br Med J 1989; 299: 762-7
4. Abrams PH. The urodynamic changes following prostatectomy Urol M 1978; 33: 181-6
5. Robertson AS. Griffiths C, Neal DE. Conventional urodynamics and ambulatory monitoring in the definition and management of bladder outflow obstruction J Urol 1996; 155: 506-11
6. Isaacs JT. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologie intervention. Prostate 1990; Suppl 3: 1-7
7. Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE. Lieber MM. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996; 155: 595-600
8. Chappie CR, Noble JG. Milroy EJG. Comparative study of selective alpha-1 adrenoceptor blockade versus surgery in the treatment of prostatic obstruction. Br J Urol 1993; 72: 822-5
9. Kaplan SA, Goluboff ET, Olsson CA, Deverka PA, Chmiel TJ. Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia. Urology 1995; 45: 398-405
10. Guschin BL, Jones CA, Nyberg LM. Decline in the surgical treatment of benign prostatic hyperplasia (BPH) from 1985-94. J Urol 1997; 157: 1211A
11. Fitzpatrick JM, Lynch TH. Phytotherapeutic agents in the management of symptomatic benign prostatic hyperplasia. Urol Clin North Am 1995: 22: 407-12
12. Berges RR. Senge T. Trampisch HJ. Windeler J. Randomised placebo-controlled, double -blind clinical trial of beta-sitosterolin patients with benign prostatic hyperplasia. Lancet 1995: 345: 1529-32
13. 3 Grasso M. Borghi C, Cesana BM et al. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol 1995: 48: 97-103
14. Carraro JC. Perrin P. Perler A et al. Comparison of phytotherapy (Permixon) with flnasteride in the treatment of benign prostatic hyperplasia: a randomised international study of 1,098 patients. Prostate 1996: 29: 231-40
15. Gingell JC. Tunn UW. Kurth KH. Knonagel H. Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. J Urol 1995: 154: 399-401
16. Imperato-McGinley J. Guevro L. Gauteri T et al. Steroid 5 alpha reductase deficiency in man: inherited form of pseudo hermaphroditism. Science 1974: 186: 1213-5
17. 7 Guess HA. Hayes GF. Gormley GJ. Effect of finasteride on prostate specific antigen in men with benign prostatic hyperplasia. Prostate 1993; 22: 31-7
18. Stone F. Finasteride study group -the clinical effects of a 5α reductase inhibitor Finasteride on benign prostatic hyperplasia. J Urol 1992; 147: 1298-302
19. Tempany CMC. Partin AW, Zerhouni A. Zinreich SJ. Walsh PC. The influence of Finasteride on the volume of the peripheral and periurethral zones of the prostate in men with prostatic hyperplasia. Prostate 1993; 22: 39-42
20. Gormley GA. Stoner F. Bruskewitz RC et al. The effect of tinasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. A' Eng J Med 1992: 327: 1185-91
21. Finasteride study group. Finasteride (MK906) treatment for benign prostatic hyperplasia. Prostate 1993; 22: 291-9
22. Andersen JT, Ekman P. Wolf H et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two year placebo controlled study. Urology 1995; 46: 631-7
23. 3 Nickel JC. Elhilali MM. Afridi SK et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomised controlled trial [the PROSPECT trial). CMAJ 1996; 155: 1251-9
24. Andersen JT. Nickel JC. Marshall VR, Schulman CC, Boyle P. Finasteride significantly reduces acute urinary retention and need for surgery in patients with benign prostatic hyperplasia. Urology 1997; 49: 839-45
25. Neal DE. Watchful waiting or drug therapy for benign prostatic hyperplasia Lancet 1997: 350: 305-6
26. Lepor H. Williford WO. Barry MJ et al. The efficacy of terazosin, finasteride. or both in benign prostatic hyperplasia. New EngJ Med 1996; 335: 533-9
27. Boyle P, Gould AL. Roehrborn CG. Prostate volume predicts outcome of treatment in benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996: 48: 398-405
28. Leamonth A contribution to the neurophysiology of the urinary bladder in man. Brain 1931; 54: 147-76
29. Furuya S. Kumamoto Y. Yokoyama E. Tsukamoto T, Izumi T. Abiko Y. Alpha-adrenergic activity and urethral pressure profilimetry in prostatic zone in benign prostatic hyperplasia. J Urol 1982: 128: 836-9
30. Donker PJ, Ivanovici F, Noach EL. Analyses of the urethral pressure profile by means of electromyography and the administration of drugs. ErJ Ural 1972: 44: f 80-9 3
31. Caine M, Raz S. Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br JUrol 1975; 47: 193-202
32. James S, Chappie CR, Phillips MI, Burnstock G. Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in hyperplastic human prostate. J Urol 1989: 142: 438-44
33. 3 Kobayashi S. Tang R. Shapiro E, Lepor H. Characterisation and localisation of prostatic alpha 1 adrenoceptors using radioligand receptor binding on slide mounted tissue section. J Urol 1993; 150: 2002-6
34. Perlberg S. Caine M. Adrenergic response of bladder muscle in prostatic obstruction. Uroloaij 1982; 20: P524-7
35. Smith UJ, Chappie CR. In vitro response of human bladder smooth muscle in unstable obstructed male bladders: a study of pathophysiological causes. Neurourol Urodynam 1994: 13: 414-5
36. Boreham PF. Braithwaite P. Mileswki P, Pearson H. Alpha-adrenergic blockers in prostatism. Br J Surg 1977: 4: 758-7
37. Caine M. Perlberg S. Meretyk S. A placebo-controlled double-blind study on the effect of phenoxybenzamine in benign prostatic obstruction. Br JUrol 1978: 50: 551-4
38. Abrams PH. Shah PStone AR, Choa RG. Bladder outflow obstruction treated with phenoxybenzamine. Pro0 Clin Biol Res 1981; 78: 269-75
39. Abrams PH. Shah PChoa RG. Bladder outflow obstruction treated with phenoxybenzamine. Br J Urol 1982: 54: 527-30
40. Gerstenberg T. Blaabjerg J. Nielsen ML. Clausen S. Phenoxybenzamine reduces bladder outlet obstruction in benign prostatic hyperplasia. A urodynamic investigation. Invest Urol 1980; 18: 29-31
41. Brooks ME. Sidi AA. Hanani Y. Braf AF. Ineffectiveness of phenoxybenzamine in treatment of benign prostatic hypertrophy. A controlled study. Urology 1983; 21: 474-8
42. Thien T. Delaere KP. Debruyne FM et al. Urinary incontinence caused by prazosin. BrMedJ 1978; 2: 622-3
43. Kirby RS. Coppinger SWC. Corcoran MO. Chappie CR. Flannagan M, Milroy EJG. Prazosin in the treatment of prostatic obstruction: a placebo-controlled study. Br J Ural 1987: 50: 136-42
44. McGrath JC. Evidence for more than one type of postjunctional a-adrenoceptor. Biochem Pharmacol 1982; 31: 467-84
45. Ford APDW. Williams TJ. Blue DR. a.-adrenoceptor classification: sharpening Occam's razor. 77P.S" 1994: 15: 167-70
46. Hieble JP, Bylund DB, Clarke DE et ni. International Union of Pharmacology. X. Recommendation of nomenclature of aradrenoceptors: consensus update. Pharmacol Rev 1995; 47: 267-70
47. Chappie CR. Burt RP. Marshall I. at adrenoceptor subtypes in the human prostate and inferior epigastric artery. Neurourol Urodyn 1991: 10: 306-8
48. Yamada S. Suzuki M, Tanaka C et al. Binding characteristics of otj blockers to a, adrenoceptors in human prostate and aorta. Abstract 5th World Conference on Clinical Pharmacology and Therapeutics. Yokohama, Japan. 1992
49. Lomasney JW. Cotecchia S. Lorenz W el al. Molecular cloning and expression of the cDNA for the otla-adrenergic receptor. ; Biol Chem 1991: 266: 6365-9
50. Cotecchia S, Schwinn DA, Randall RR et al Molecular cloning and expression of the cDNA for the hamster α-
51. adrenergic receptor. Proc Nad Acad Sä USA 1988: 85: 7159-63
52. Schwinn DA, Lomasney JW, Lorenz W et al. Molecular cloning and expression of the cDNA for a novel ar adrenergic receptor subtype. J Bio/ Chem 1990; 265: 8183-9
53. Ferez DM. Piascik MT, Graham RM. Solution-phase library screening for the identification of rare cloned isolation of an otld adrenergic receptor cDNA. Mol Pharmacol 1991: 40: 876-83
54. Schwinn DA, Lomasney JW. Pharmacological characterisation of cloned oij-adrenoceptor subtypes: selective antagonists suggest the existence of a fourth subtype. Eur J Pharmacol Mol Pharmacol 1992; 227: 433-6
55. Marshall I, Burt RP, Andersson PO et al. Human ar adrenoceptor functional classification in prostate. Br J Pharmacol 1992; 107: 327P
56. Chappie CR. Burt RP, Andersson PO, Greengrass P, Wyllie M, Marshall I. Alpharadrenoceptor subtypes in the human prostate. Br J Urol 1994; 74: 585-9
57. Forray C, Bard JA, Wetzel JM et al. The ocradrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alc subtype. Mol Pharmacol 1994; 45: 703-8
58. Bruno JF, Whittaker J, Song J et al Molecular cloning and sequencing of a cDNA encoding a human otla adrenergic receptor. Biochem Biophys Res Commun 1991; 179: 1485-90
59. Ramarao CS, Kincade Denker JM et al. Genomic organisation and expression of the human alb adrenergic receptor. J Bio/ Chem 1992; 267: 21936-45
60. Hirasawa AK, Horie T, Tanaka K et al. Cloning, functional expression and tissue distribution of human cDNA for the ot,c adrenergic receptor. Biochem Biophys Res Commun 1993; 195: 902-9
61. Price DT, Schwinn DA, Lomasney JW, Alien LF, Caron MG, Lefkowitz RJ. Identification, quantification, and localization of mRNA for three distinct alphaj adrenergic receptor subtypes in human prostate. J Urol 1993: 150: 546-51
62. Schalken JA, Van Stratum P, Smit F et al. Differential expression of alpha 1-adrenergic receptor subtypes in BPH determined by reverse transcriptase PCR (Polymerase Chain Reaction). Proceedings of the 23rd Congress of the Société Internationale d'Urologie, Sydney, 18-22 September 1994: 253 (A48)
63. Yamada S, Tanaka C, Kimura R, Kawabe K. Alphar adrenoceptors in human prostate: characterization and binding characteristics of alphaj-antagonists. Life Sci 1994; 54: 1845-54
64. Hatano A, Takahashi H, Tamaki M, Komeyama T, Koizumi T, Takeda M. Pharmacological evidence of distinct a,-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol 1994; 113: 723-8
65. Muramatsu IM, Oshita T, Ohmura S et al. Pharmacological characterisation of α-adrenoceptor subtypes in the human prostate: functional and binding studies. Br JUrol 1994; 74: 572-7
66. Ford APDW, Arredondo NF, Blue DR et al. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy) ethylJ-5-chloro-a, a-dimethyl-lH-indole-3-ethanamine hydrochloride), a selective a1A-adrenoceptor antagonist, displays low affinity for functional aradrenoceptors in human prostate: impli-cations for adrenoceptor classification. Mol Pharmacol 1996; 49: 209-15
67. Mason SL, Davis BJ, Chappie CR et al. Identification of the a1L adrenoceptor subtype in human prostate and rat salivary gland using radioligand binding with [3HJ tamsulosin. Er J Pharmacol 1997; 122: 283P
68. Ford APDW, Danniels DV. Chang DJ et al. Pharmacological pleiotropism of the human recombinant a1A adrenoceptor: implications for receptor classification Br JPharmacol 1997; 121: 1127-35
69. Chess-Williams R, Michel MC, Couldwell CJ et al. The effects of SB 216469, an antagonist which discriminates between the oc1A adrenoceptor and the human prostatic a, adrenoceptor. Br J Pharmacol 1996; 119: 1093-100
70. Testa R, Guarneri L, Angelico P et al. pharmacological characterisation of the uroselective alpha 1 antagonist Rec 15/2739 (SB 216469): Role of the alpha-lL adrenoceptor in tissue selectivity, Part 11. J Pharm Exp Ther 1997; 281: 1284-93
71. Anderson KE on behalf of the Alpha blocker therapy committee in BPH. The Third International Consultation in BPH. Scientific Communication International Ltd 1996: 541-2
72. Martin DJ, Lluel P, Guillot E et al. Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharm Exp Ther 1997: 282: 228-35
73. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P and the BPH-ALF Group. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 1991; 337: 1457-61
74. Buzelin JM, Hebert M, Blondin P, and the PRAZALF Group. Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. Br J Urol 1993; 72: 922-7
75. Buzelin JM, Roth S, Geffriaud-Ricouard C, DelaucheCavallier MC and the ALGEBI study group. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. Eur Urol 1997; 31: 190-8
76. Lepor H, Auerbach S, Puras-Baez A et al. A randomized, placebo-controlled, multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148: 1467-74
77. Brawer MK, Adams G, Epstein H and the Terazosin Benign Prostatic Hyperplasia Study Group. Terazosin in the treatment of benign prostatic hyperplasia. Arch Fam Med 1993; 2: 929-35
78. Roehrborn CG, Oesterling JE, Auerbach S et al. for the HYCAT Investigator Group. The HYtrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 1996; 47: 159-68
79. Elhilali MM, Ramsay EW, Barkin J et al. A multicentre, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology 1996; 47: 335-42
80. Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N, for the Multicenter Study Group. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105-9
81. Gillenwater JY, Conn RL, Chrysant SG et al. for the Multicenter Study Group. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebocontrolled, dose-response multicenter study. J Urol 1995; 154: 110-5
82. Roehrborn CG, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology 1996; 48: 406-15
83. Abrams P. Speakman M. Stott M. Arkell D, Pocock R. A dose-ranging study of the efficacy and safety of tamsulosin. the first prostate-selective a,A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic BPH). BrJ Ural 1997; 80: 587-96
84. Abrams P. Schulman CC, Vaage S. and the European Tamsulosin Study Group. Tamsulosin, a selective cxlcadrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). BrJ Urol 1995: 76: 325-36
85. Chappie CR. Wyndaele JJ, Nordling J, Boeminghaus F. Ypma AFGVM, Abrams P. Tamsulosin. the first prostateselective aJA-adrenoceptor antagonist: a meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 155-67
86. Lepor H. and the Tamsulosin Investigator Group. Longterm evaluation of tamsulosin. a prostate selective alpha, antagonist. J Urol 1996: 155: 585A (A1099)
87. Christensen MM, Holme JB. Rasmussen PC et al. Doxazosin treatment in patients with prostatic obstruction. Smnd J Urol Nephrol 1993; 27: 39-44
88. Chappie CR, Carter P, Christmas TJ et al. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br JUrol 1994; 74: 50-6
89. Kawabe K, Ueno A. Takimoto Y. Aso Y. Kalo H and the the YM617 clinical study group. Use of an od-blocker. YM617. in the treatment of benign prostatic hypertrophy. J Urol 1990; 144: 908-12
90. Löwe FC. Safety assessments of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology 1994; 44: 46-51
91. Janknegt RA, Chappie CR. For the doxazosin study groups. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia Analysis of 5 studies. Eur Urol 1993; 24: 319-26
92. Fulton B, Wagstaff AJ. Sorkin EM. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995; 49: 295-320
93. Buzelin JM, Delauche-Cavallier MC. Roth S et al. Clinical uroselectivity: evidence from patients treated with slowrelease alfuzosin for symptomatic benign prostatic obstruction. Br J Urol 1997: 79: 898-906
94. Lefevre-Borg F. O'Connor SE, Schoemaker H et al. Alfuzosin, a selective alpha-1 adrenoceptor antagonist in the lower urinary tract. Br J Pharmacol 1993; 109: 1282-9
95. Michel MC. Büscher R, Kerker J. Kraneis H, Erdbrügger W. Brodde 0-E. a,-Adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Evidence for heterogeneity of chloroethylclonidine-resistant rat renal a,-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 1993; 348: 385-95
96. Chappie CR, Couldwell CJ, Noble AJ. Chess-Williams R. The in-vitro otj adrenoceptor mediated effects of tamsulosin on the human prostate. Proceedings of the 23rd Congress of the Société Internationale d'Urologie. Sydney. 18-22 September 1994: 210 (A487)
97. Michel MC. Insel P. A comparison of cloned and pharmacologically defined rat tissue α-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacal 1994: 350: 136-42
98. Testa R. Poggessi E, Taddei C. Guarneri L. Ibba M, Leonard! A. REC 15/2739, a new α-antagonist selective for the lower urinary tract: in vitro studies. Neurourol Urodynam 1994: 13: 473-4 (A84B)
99. Foglar R. Shibata K. Horie K. Hirasawa A. Tsujimoto G. Use of recombinant α-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur JPharmacol 1995: 288: 201-7
100. Ban C. Hollinger S. Theroux TL. Esbenshade TA. Minneman KP. 5H-Tamsulosin binding to cloned ajadrenergic receptor subtypes stably expressed in human embryonic kidney 293 cells: antagonist potencies and sensitivity to inactivation by alkylating agents. Pharmacol Commun 1995; 5: 117-26
101. Michel MC. Grübbel B. Taguchi K, Verfürth F, Otto T. Kröpfl D. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned α-adrenoceptor subtypes and in human prostate. J Auton Pharmacol 1996; 16: 21-8
102. Richardson CD. Donatucci CF. Page SO. Wilson KH. Schwinn DA. Pharmacology of tamsulosin: saturation binding isotherms and competition analysis using cloned aradrenergic receptor subtypes. Prostate 1997: 33: 55-9
103. Yamada S. Suzuki M. Tanaka C et al. Comparative study on cx,-adrenoceptor antagonist binding in human prostate and aorta. Clin Exp Pharmacol Physiol 1994: 21: 405-11
104. Harada K. Ohmori M. Fujimura A. Comparison of the antagonistic activity of tamsulosin and doxazosin at vascular α-adrenoceptors in humans. Naunyn-Schmiedeberg's Arch Pharmacol 1996: 354: 557-61
105. Rabasseda X. Fitzpatrick JM. Tamsulosin: the first prostateselective 31A-adrenoceptor antagonist for the treatment of symptomatic benign prostatic hyperplasia. Drugs Today 1996: 32: 259-68
106. Chappie CR. for the European Tamsulosin Study Group. Tamsulosin: tolerability in older and younger symptomatic Bl'H patients. J Urol 1996: 155: 575A (A1057)
107. Schulman CC. Cortvriend J. Jonas U. Lock TMTW. Vaage S, Speakman MJ. Tamsulosin. the first prostate-selective a1A-adrenoceptor antagonist: an interim analysis of a multinational, multicentre. open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 145-54
108. Starkey LP. Yasukawa K. Trenga C. Miyazawa Y. I to Y. Study of possible pharmacodynamic interaction between tamsulosin and nifedipine in subjects with essential hypertension. J Clin Pharmacol 1994: 34: 1019 (A45)
109. Starkey LP. Trenga C. Miyazawa Y. Ito Y. Lack of clinical interaction effects between tamsulosin and enalapril. Clin Pharmacol Ther 1995: 57: 166 (API1-11)
110. Löwe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther 1997: 19: 730-42